Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
European Cardiovascular Research Center
Information provided by (Responsible Party):
MINVASYS
ClinicalTrials.gov Identifier:
NCT01485081
First received: November 14, 2011
Last updated: November 8, 2013
Last verified: November 2013
  Purpose

The purpose of this study is to assess the safety and efficacy of the Danubio Paclitaxel Eluting Balloon for the treatment of side branches of de novo bifurcation lesions in native coronary arteries.


Condition Intervention
Coronary Disease
Device: Danubio paclitaxel-eluting balloon

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of Side Branches of de Novo Bifurcation Lesions in Native Coronary Arteries.

Resource links provided by NLM:


Further study details as provided by MINVASYS:

Primary Outcome Measures:
  • Late Lumen Loss (mm) in Side Branche (SB) [ Time Frame: 6 months post-procedure (up to 26 weeks) ] [ Designated as safety issue: No ]
    Late Lumen Loss at the ostium of the SB (within 5mm from the carina) by Quantitative Coronary Angiography (QCA).


Secondary Outcome Measures:
  • In-stent Late Lumen Loss (mm) in Main Branch (MB) [ Time Frame: 6 months post-procedure (up to 26 weeks) ] [ Designated as safety issue: No ]
    In-stent Late Lumen Loss in the MB by QCA.

  • Angiographic Binary Restenosis rate (%) [ Time Frame: 6 months post-procedure (up to 26 weeks) ] [ Designated as safety issue: No ]
    Angiographic binary restenosis rate (%) in the side and main branches by QCA.

  • Major Adverse Cardiac Event (MACE) rate [ Time Frame: In-hospital, 1, 6 and 12 months post-procedure. ] [ Designated as safety issue: Yes ]
    MACE defined as death, Myocardial Infarction (MI, Q waves and non-Q waves), emergent cardiac bypass surgery, or any target lesion revascularization (repeat Percutaneous transluminal coronary angioplasty (PTCA) or Coronary artery bypass grafting (CABG)).

  • Clinically-driven Target Lesion Revascularization (TLR) [ Time Frame: 1, 6 and 12 months post-procedure ] [ Designated as safety issue: Yes ]
  • Target Vessel Failure (TVF) [ Time Frame: 1, 6 and 12 months post-procedure ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 1, 6 and 12 months post-procedure ] [ Designated as safety issue: Yes ]
  • Angiographic success [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: May 2012
Estimated Study Completion Date: July 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Danubio Device: Danubio paclitaxel-eluting balloon
Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.

Detailed Description:

The DEBSIDE clinical trial is a prospective, non-randomized, multicenter, interventional study evaluating the investigational Danubio Paclitaxel Eluting Coronary Balloon for the treatment of Side Branches (SB) of de novo bifurcation lesions with a side branch reference vessel diameter ≥2.0 mm and ≤3.0 mm. During the procedure, a dedicated drug-eluting bifurcated stent will be implanted in the main branch. The trial will allow the treatment of lesion of all Medina type except (0,0,1) in native coronary arteries with sequential predilatation of the main and side branch.

The DEBSIDE clinical trial will enroll 60 patients. All patients will receive Quantitative Coronary Angiography (QCA) before and after Drug-Eluting Balloon (DEB) inflation and at 6 months follow-up. All patients will have a clinical follow-up at 1, 6 and 12 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. De novo bifurcation lesions following the Medina classification except (0,0,1).
  2. Reference diameter main branch >= 2.5 and ≤ 3.5 mm and side branch >= 2.0 and ≤ 3.0 mm.
  3. Main branch lesion length ≤ 26mm and side branch lesion ≤ 6mm.

    • For a 24mm stent in the main branch: main branch lesion length ≤ 14mm proximal and ≤ 12mm distal to the carina.
    • For a 18mm stent in the main branch: main branch lesion length ≤ 8mm proximal and ≤ 12mm distal to the carina.

    Indeed an additional stent (Amazonia PAX 8mm) can be overlapped distally with the Nile PAX if a target lesion segment ≤4mm remains uncovered after implantation of the bifurcated stent.

  4. Maximum two bifurcation lesions per patient on two different vessels with at least one lesion treated with the procedure described on the protocol (involving the Danubio).
  5. The side branch of the bifurcation involving the target lesion must be treated with the trial device (Danubio).
  6. During the index procedure, in case of:

    • Treatment of a lesion in a vessel other than the target vessel or,
    • Treatment of a lesion in the target vessel distal to the target bifurcation lesion, The treatment of the non-target lesion must be successfully performed with a Drug-Eluting Stent before the treatment of the target lesion (residual stenosis <30%; stent well deployed; no residual dissection; normal TIMI flow; no chest pain; ECG unchanged compared to pre-procedural ECG).
  7. Successful sequential main branch and side branch predilatation with a conventional balloon providing good angiographic result (i.e. absence of dissection, TIMI > III).
  8. The patient is at least 18 years of age.
  9. Non menopausal women must provide a negative pregnancy test and use a double contraception until the end of the study.
  10. The patient has clinical evidence of ischemic heart disease, stable or unstable angina with signs of ischemia, silent ischemia, or a positive functional test.
  11. The patient is an acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), stenting, and emergent coronary artery bypass graft (CABG) surgery.
  12. The patient or patient's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the Ethics Committee (EC).
  13. The patient agrees to return to the same research facility for required angiographic post-procedure follow-up visit at 6 months

Exclusion Criteria:

  1. De novo bifurcation lesion Medina (0,0,1).
  2. Left main bifurcation.
  3. The Danubio covers beyond the side branch lesion distally with <2mm.
  4. The stent covers beyond the main branch lesion proximally and distally with <2mm.
  5. Heavily calcified lesions.
  6. Severe tortuous lesions.
  7. Evidence of extensive thrombosis or dissection within target vessel before the intervention
  8. Documented left ventricular ejection fraction (LVEF) <30% at most recent evaluation.
  9. Main branch of the target lesion stented with other device than Nile PAX.
  10. Dissection or required additional treatment in the main or side branch of the target lesion after main branch stent implantation.
  11. Untreated significant lesion >50% diameter stenosis remaining proximal or distal to the target lesion
  12. A known hypersensitivity or contraindication to aspirin, heparin or bivaluridin, ticlopidine or clopidogrel, paclitaxel or drugs in similar class, cobalt chromium alloys, contrast media, which cannot be adequately pre-medicated.
  13. Chronic total occlusion (CTO).
  14. A serum creatinine level >2.0mg/dL within seven days prior to index procedure.
  15. Evidence of an acute MI within 72 hours of the intended index procedure (according to ARC definition).
  16. Previous Percutaneous Coronary Interventions (PCI) of the target lesion.
  17. Previous PCI of the target vessel within 9 months pre-procedure.
  18. Planned PCI of any vessel within 30 days post-procedure.
  19. Surgery 30 days prior to this PCI or anticipated surgery 6-months post this PCI.
  20. During the index procedure, the target lesion requires treatment with a device other than PTCA prior to use of Danubio (including but not limited to cutting balloon, any atherectomy, any laser, thrombectomy, etc.).
  21. Second lesion requiring treatment in target vessel.
  22. Second bifurcation lesion requiring treatment.
  23. History of a stroke or transient ischemic attack (TIA) within the prior 6 months.
  24. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months.
  25. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  26. Concurrent medical condition with a life expectancy of less than 12 months.
  27. Any previous or planned treatment of the target vessel with anti-restenotic therapies including, but not limited to brachytherapy.
  28. Currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints, or requires coronary angiography, IVUS or other coronary artery imaging procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01485081

Locations
France
Pôle Santé République
Clermont Ferrand, France, 63050
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003
Centre Cardiologique d'Evecquemont
Evecquemont, France, 78740
Institut hospitalier Jacques Cartier
Massy, France, 91300
CHU Nantes
Nantes, France, 44093
Clinique Saint-Hilaire
Rouen, France, 76000
Clinique Pasteur
Toulouse, France, 31076
Sponsors and Collaborators
MINVASYS
European Cardiovascular Research Center
Investigators
Principal Investigator: Jacques BERLAND, MD Clinique Saint Hilaire - ROUEN
  More Information

No publications provided

Responsible Party: MINVASYS
ClinicalTrials.gov Identifier: NCT01485081     History of Changes
Other Study ID Numbers: MIN1101
Study First Received: November 14, 2011
Last Updated: November 8, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: Committee for the Protection of Personnes
France: Conseil National de l'Ordre des Médecins

Keywords provided by MINVASYS:
Bifurcation
Drug-eluting balloon
Paclitaxel-eluting balloon
Angioplasty
Coronary artery disease
Coronary artery stenosis

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Paclitaxel
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on October 22, 2014